434 related articles for article (PubMed ID: 24925721)
1. Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease.
Yoo TH; Pedigo CE; Guzman J; Correa-Medina M; Wei C; Villarreal R; Mitrofanova A; Leclercq F; Faul C; Li J; Kretzler M; Nelson RG; Lehto M; Forsblom C; Groop PH; Reiser J; Burke GW; Fornoni A; Merscher S
J Am Soc Nephrol; 2015 Jan; 26(1):133-47. PubMed ID: 24925721
[TBL] [Abstract][Full Text] [Related]
2. Sphingomyelinase-like phosphodiesterase 3b mediates radiation-induced damage of renal podocytes.
Ahmad A; Mitrofanova A; Bielawski J; Yang Y; Marples B; Fornoni A; Zeidan YH
FASEB J; 2017 Feb; 31(2):771-780. PubMed ID: 27836988
[TBL] [Abstract][Full Text] [Related]
3. Changes in podocyte TRPC channels evoked by plasma and sera from patients with recurrent FSGS and by putative glomerular permeability factors.
Kim EY; Roshanravan H; Dryer SE
Biochim Biophys Acta Mol Basis Dis; 2017 Sep; 1863(9):2342-2354. PubMed ID: 28629718
[TBL] [Abstract][Full Text] [Related]
4. RAGE and αVβ3-integrin are essential for suPAR signaling in podocytes.
Kim EY; Dryer SE
Biochim Biophys Acta Mol Basis Dis; 2021 Oct; 1867(10):166186. PubMed ID: 34166766
[TBL] [Abstract][Full Text] [Related]
5. SMPDL3b modulates insulin receptor signaling in diabetic kidney disease.
Mitrofanova A; Mallela SK; Ducasa GM; Yoo TH; Rosenfeld-Gur E; Zelnik ID; Molina J; Varona Santos J; Ge M; Sloan A; Kim JJ; Pedigo C; Bryn J; Volosenco I; Faul C; Zeidan YH; Garcia Hernandez C; Mendez AJ; Leibiger I; Burke GW; Futerman AH; Barisoni L; Ishimoto Y; Inagi R; Merscher S; Fornoni A
Nat Commun; 2019 Jun; 10(1):2692. PubMed ID: 31217420
[TBL] [Abstract][Full Text] [Related]
6. suPAR and chronic kidney disease-a podocyte story.
Zeier M; Reiser J
Pflugers Arch; 2017 Aug; 469(7-8):1017-1020. PubMed ID: 28689240
[TBL] [Abstract][Full Text] [Related]
7. IGFBP-1 expression is reduced in human type 2 diabetic glomeruli and modulates β1-integrin/FAK signalling in human podocytes.
Lay AC; Hale LJ; Stowell-Connolly H; Pope RJP; Nair V; Ju W; Marquez E; Rollason R; Hurcombe JA; Hayes B; Roberts T; Gillam L; Allington J; Nelson RG; Kretzler M; Holly JMP; Perks CM; McArdle CA; Welsh GI; Coward RJM
Diabetologia; 2021 Jul; 64(7):1690-1702. PubMed ID: 33758952
[TBL] [Abstract][Full Text] [Related]
8. Recurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin Activation.
Staeck O; Slowinski T; Lieker I; Wu K; Rudolph B; Schmidt D; Brakemeier S; Neumayer HH; Wei C; Reiser J; Budde K; Halleck F; Khadzhynov D
Transplantation; 2015 Dec; 99(12):2593-7. PubMed ID: 26371597
[TBL] [Abstract][Full Text] [Related]
9. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.
Wei C; El Hindi S; Li J; Fornoni A; Goes N; Sageshima J; Maiguel D; Karumanchi SA; Yap HK; Saleem M; Zhang Q; Nikolic B; Chaudhuri A; Daftarian P; Salido E; Torres A; Salifu M; Sarwal MM; Schaefer F; Morath C; Schwenger V; Zeier M; Gupta V; Roth D; Rastaldi MP; Burke G; Ruiz P; Reiser J
Nat Med; 2011 Jul; 17(8):952-60. PubMed ID: 21804539
[TBL] [Abstract][Full Text] [Related]
10. Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes.
Alfano M; Cinque P; Giusti G; Proietti S; Nebuloni M; Danese S; D'Alessio S; Genua M; Portale F; Lo Porto M; Singhal PC; Rastaldi MP; Saleem MA; Mavilio D; Mikulak J
Sci Rep; 2015 Sep; 5():13647. PubMed ID: 26380915
[TBL] [Abstract][Full Text] [Related]
11. Podocyte pathology and nephropathy - sphingolipids in glomerular diseases.
Merscher S; Fornoni A
Front Endocrinol (Lausanne); 2014; 5():127. PubMed ID: 25126087
[TBL] [Abstract][Full Text] [Related]
12. Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy.
Alachkar N; Wei C; Arend LJ; Jackson AM; Racusen LC; Fornoni A; Burke G; Rabb H; Kakkad K; Reiser J; Estrella MM
Transplantation; 2013 Oct; 96(7):649-56. PubMed ID: 23842190
[TBL] [Abstract][Full Text] [Related]
13. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis.
Fornoni A; Sageshima J; Wei C; Merscher-Gomez S; Aguillon-Prada R; Jauregui AN; Li J; Mattiazzi A; Ciancio G; Chen L; Zilleruelo G; Abitbol C; Chandar J; Seeherunvong W; Ricordi C; Ikehata M; Rastaldi MP; Reiser J; Burke GW
Sci Transl Med; 2011 Jun; 3(85):85ra46. PubMed ID: 21632984
[TBL] [Abstract][Full Text] [Related]
14. Further Evidence That the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes.
Harel E; Shoji J; Abraham V; Miller L; Laszik ZG; King A; Dobi D; Szabo G; Hann B; Sarwal MM; Craik CS; Vincenti F
Transplantation; 2020 Jan; 104(1):54-60. PubMed ID: 31449183
[TBL] [Abstract][Full Text] [Related]
15. Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice.
Cathelin D; Placier S; Ploug M; Verpont MC; Vandermeersch S; Luque Y; Hertig A; Rondeau E; Mesnard L
J Am Soc Nephrol; 2014 Aug; 25(8):1662-8. PubMed ID: 24790179
[TBL] [Abstract][Full Text] [Related]
16. Sphingomyelin Phosphodiesterase Acid-Like 3b is Essential for Toll-Like Receptor 3 Signaling in Human Podocytes.
Watanabe S; Hidenori U; Hashimoto S; Riko S; Aizawa T; Tsugawa K; Imaizumi T; Tanaka H
J Membr Biol; 2022 Feb; 255(1):117-122. PubMed ID: 34739556
[TBL] [Abstract][Full Text] [Related]
17. Contribution of guanine nucleotide exchange factor Vav2 to NLRP3 inflammasome activation in mouse podocytes during hyperhomocysteinemia.
Conley SM; Abais-Battad JM; Yuan X; Zhang Q; Boini KM; Li PL
Free Radic Biol Med; 2017 May; 106():236-244. PubMed ID: 28193546
[TBL] [Abstract][Full Text] [Related]
18. RhoA protects the podocytes against high glucose-induced apoptosis through YAP and plays critical role in diabetic nephropathy.
Huang Z; Peng Y; Yu H; Yu X; Zhou J; Xiao J
Biochem Biophys Res Commun; 2018 Oct; 504(4):949-956. PubMed ID: 30220545
[TBL] [Abstract][Full Text] [Related]
19. MYDGF attenuates podocyte injury and proteinuria by activating Akt/BAD signal pathway in mice with diabetic kidney disease.
He M; Li Y; Wang L; Guo B; Mei W; Zhu B; Zhang J; Ding Y; Meng B; Zhang L; Xiang L; Dong J; Liu M; Xiang L; Xiang G
Diabetologia; 2020 Sep; 63(9):1916-1931. PubMed ID: 32588068
[TBL] [Abstract][Full Text] [Related]
20. Kindlin-2 Association with Rho GDP-Dissociation Inhibitor
Sun Y; Guo C; Ma P; Lai Y; Yang F; Cai J; Cheng Z; Zhang K; Liu Z; Tian Y; Sheng Y; Tian R; Deng Y; Xiao G; Wu C
J Am Soc Nephrol; 2017 Dec; 28(12):3545-3562. PubMed ID: 28775002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
